About Us

About Array

At Array, we embrace three core values that guide our day-to-day activities:

    1. Integrity and transparency in what we do and how we do it
    2. A sense of urgency and creativity in bringing benefit to patients
    3. The knowledge to achieve our critical objectives

Array Today
Ten registration studies are currently advancing related to eight Array-owned or partnered drugs: encorafenib (LGX818), binimetinib (MEK162), ARRY-797, selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Seattle Genetics).